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Abstract
Background Current guidelines advocate use of arteriovenous fistula (AVF) over central venous catheter (CVC) for children
starting hemodialysis (HD). European data on current practice, determinants of access choice and switches, patient survival, and
access to transplantation are limited.
Methods We included incident patients from 18 European countries who started HD from 2000 to 2013 for whom vascular
access type was reported to the ESPN/ERA-EDTA Registry. Data were evaluated using descriptive statistics, logistic and Cox
regression models, and cumulative incidence competing risk analysis.
Results Three hundred ninety-three (55.1%) of 713 children started HD with a CVC and were more often females, younger, had
more often an unknown diagnosis, glomerulonephritis, or vasculitis, and lower hemoglobin and height-SDS at HD initiation.
AVF patients were 91% less likely to switch to a second access, and two-year patient survival was 99.6% (CVC, 97.2%).
Children who started with an AVF were less likely to receive a living donor transplant (adjusted HR, 0.30; 95% CI, 0.16–
0.54) and more likely to receive a deceased donor transplant (adjusted HR, 1.50; 95% CI, 1.17–1.93), even after excluding
patients who died or were transplanted in the first 6 months.
Conclusions CVC remains the most frequent type of vascular access in European children commencing HD. Our results suggest
that the choice for CVC is influenced by the time of referral, rapid onset of end-stage renal disease, young age, and an expected
short time to transplantation. The role of vascular access type on the pattern between living and deceased donation in subsequent
transplantation requires further study.
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Access to transplantation
Introduction
European Best Practice Guidelines state minimizing dialysis
time and performing kidney transplantation as early as possi-
ble as important treatment goals in the care of children [1–3].
However, pre-emptive transplantation is not always feasible,
and dialysis is initiated in the majority of children starting
renal replacement therapy (RRT) [4, 5].
Vascular access options for hemodialysis (HD) are arterio-
venous fistulas (AVF), arteriovenous grafts (AVG), or central
venous catheters (CVC). The Kidney Disease Outcome
Quality Initiative Guidelines recommend using AVF as per-
manent access for most children on maintenance HD [6].
International initiatives, like the “International Pediatric
Fistula First Initiative,” propagate an increased use of AVF
instead of CVC [7–9].
Despite these recommendations, the percentage of CVC
is still high and even seems to be increasing during recent
years in the United States (USA) [10]. However, due to
small patient numbers in pediatric dialysis units, there are
limited data on current vascular access practices and the
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clinical course of pediatric patients commencing RRT on
HD in Europe.
We therefore aimed to (i) analyze current practice in
European countries with respect to vascular access in pediatric
HD, (ii) evaluate differences in patient characteristics and clin-
ical course, and (iii) investigate the association of first vascular
access type for HD with access to renal transplantation and
patient survival on RRT in children. To this end, we used data
from the population-based European Society for Pediatric
Nephrology (ESPN)/European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA) Registry.
Methods
Data collection
Thirty-eight European countries collect and provide individu-
al patient data to the ESPN/ERA-EDTA Registry. A detailed
description of the Registry can be found elsewhere [11]. For
the current study, we included data of all patients starting RRT
on HD from 1 January 2000 to 31 December 2013 for whom
the vascular access type was reported (Online Resource 1).
Data were obtained for the following variables: date of birth,
sex, primary renal disease (PRD), start date of HD, date of
follow-up measurements, types and dates of switches of treat-
ment modality, date and cause of death, date of end of follow-
up, vascular access type, hemoglobin, prescription of
erythropoiesis-stimulating agent (yes/no), height and height
standard deviation scores (SDS) at start of HD, and donor type
for patients receiving a renal transplant.
Definition of variables
Type of vascular access was coded as “AVF” (arteriovenous
fistula), “AVG” (arteriovenous graft), or “CVC” (central venous
catheter). Because of the low numbers of AVGs (n = 19), we
excluded these patients from the analyses. Treatment modality
changes and events were categorized as “switch of vascular ac-
cess” (i.e., need for or transition to a second vascular access),
“peritoneal dialysis” (PD), “recovery of renal function,” “renal
transplantation” (TX) stratified by donor source, i.e., “living do-
nor” (LD) and “deceased donor“(DD), or “death.” We defined
age groups (< 6 years, 6 < 12 years, 12 < 16 years ≥ 16 years) and
categorized the PRD according to the ERA-EDTA PRD codes
for children [12]. Height SDS were calculated using recent
national or European height-for-age charts [13].
Statistical analysis
Data are shown as median and interquartile range (IQR) for
continuous variables and as percentages for categorical vari-
ables. We used descriptive statistics to evaluate the differences
in clinical characteristics between patients starting on AVF or
CVC. To estimate differences in height SDS and hemoglobin
levels adjusted for age, sex, PRD, and country, linear regres-
sion was used.
Odds ratios (ORs) for the likelihood of receiving an AVF
were calculated for subgroups of patients, performing unad-
justed and adjusted hierarchical logistic regression analysis
(adjusted for sex, age group, and PRD) using a random inter-
cept for country, thereby taking into account the variation in
vascular access use across countries.
The unadjusted cumulative incidence competing risk
(CICR) analysis was performed to estimate the two-year risk
of vascular access switch [14], while Cox regression was used
to estimate the likelihood of switching adjusted for potential
confounders. Patients were followed from the start of HD until
the end of the study period (31 December 2013), switch of
RRT modality (LD or DD renal transplantation, or PD),
switch to a second vascular access, and death or recovery of
renal function, whichever occurred first.
Differences in overall access to transplantation and mortal-
ity within 2 years after HD initiation were analyzed using a
Cox regression model with country as a random effect
(correcting for clustered data within a country) and adjusted
for potential confounders.
We performed several sensitivity analyses. As the use of
AVF is less likely in young children, we repeated our analyses
excluding patients under the age of 6 years at HD initiation. To
test whether our results were representative for Europe and not
merely reflect local practices, we repeated all analyses exclud-
ing patients from France (58% of patients).
Statistical analyses were performed in SAS 9.4 (SAS
Institute, Inc. Cary, NC, USA). p values < 0.05 were consid-
ered statistically significant.
Results
Patient characteristics and determinants of first
vascular access
A total number of 4619 patients commenced HD, and data on
vascular access from 713 (15.4%) children was reported
(Online Resource 1). Patients with available data on vascular
access had a slightly higher median age at start of RRT than
those without (14.2; IQR, 10.4–17.0 vs. 13.0; IQR, 8.6–
16.0 years), while sex and PRD distribution was similar in
both groups.
AVF was the first vascular access type in 320 patients
(44.9%) and CVC in 393 patients (55.1%) (Table 1).
Patients who received an AVF were significantly older when
commencing HD, less often females, and had more often con-
genital anomalies of the kidney and urinary tract (CAKUT) as
PRD than those with a CVC, while CVC patients more often
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presented with missing/unknown diagnoses (AVF, 15.3% vs.
CVC, 23.9%). In Fig. 1, distributions of AVF and CVC strat-
ified by age and sex are reported, and potential determinants
of the first vascular access are depicted in Table 2.
Hemoglobin levels at the start of HD were significantly
higher in AVF patients. This difference remained statistically
significant after adjustment for age, sex, PRD, and country
(AVF, 10.2 g/dl and CVC, 9.1 g/dl (95% CI, 8.6–9.7);
p < 0.001). When commencing HD, AVF patients were sig-
nificantly taller than CVC patients (adjusted mean height SDS
for AVF, − 1.29 and CVC, − 1.58 (95% C, − 1.95 to − 1.20);
p = 0.049).
Table 1 Demographic and clinical characteristics of patients at the start of hemodialysis
Total AVF CVC p value
Patients n (%) 713 320 (44.9%) 393 (55.1%)
Age (years) Median (IQR) 14.2 (10.4–17.0) 14.7 (12.3–17.1) 13.6 (7.4–16.8) < 0.001
Age group n (%) < 0.001
< 6 years 91 (12.8) 13 (4.1) 78 (19.9)
6 < 12 years 139 (19.5) 59 (18.4) 80 (20.4)
12–16 years 236 (33.1) 124 (38.8) 112 (28.5)
> 16 years 247 (34.6) 124 (38.8) 123 (31.3)
Sex (female) n (%) 320 (44.9) 128 (40.0) 192 (48.9) 0.02
Primary renal disease n (%) < 0.001
Glomerulonephritis 178 (25.0) 74 (23.1) 104 (26.5)
CAKUT 210 (29.5) 117 (36.6) 93 (23.7)
Cystic kidney disease 52 (7.3) 28 (8.8) 24 (6.1)
Hereditary nephropathy 64 (9.0) 29 (9.1) 35 (8.9)
Ischemic renal failure 8 (1.1) 4 (1.3) 4 (1.0)
Hemolytic uremic syndrome 27 (3.8) 13 (4.1) 14 (3.6)
Metabolic disorders 13 (1.8) 4 (1.3) 9 (2.3)
Vasculitis 18 (2.5) 2 (0.6) 16 (4.1)
Missing/unknown diagnosis 143 (20.1) 49 (15.3) 94 (23.9)
eGFR (ml/min/1.73 m2) Median (IQR), n 8.0 (5.8–10.6), 499 8.2 (6.3–11.0), 226 7.8 (5.5–9.9), 273 0.03
Height-SDS Median (IQR), n − 1.39 (− 2.33;− 0.45), 522 − 1.35 (− 2.09;− 0.32), 230 − 1.49 (− 2.64; − 0.49), 292 0.03
Hemoglobin (g/dl) Median (IQR), n 9.5 (8.2–11.0), 429 10.4 (9.0–11.8), 182 9.1 (7.7–10.4), 247 < 0.001
ESA (yes) n (%), n 349 (89.0), 392 156 (88.1), 177 193 (89.8), 215 0.61
AVF arteriovenous fistula, CVC central venous catheter, CAKUT congenital anomalies of the kidney and urinary tract, eGFR estimated glomerular
filtration rate, SDS standard deviation score, ESA erythropoiesis stimulating agent
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Clinical course and switches of vascular access
The clinical course of patients starting HD with AVF and
CVC is presented in a flow diagram showing absolute
numbers (Fig. 2) and in a two-year cumulative incidence
competing risk plot (Fig. 3a). Median time on first vascu-
lar access was 1.0 (IQR, 0.6–1.6) years for patients
starting with an AVF and 0.5 (IQR, 0.2–1.0) years for
those who started with a CVC (p < 0.001). Most CVC
patients who received a second vascular access switched
to an AVF (97/109).
After 2 years, 28.8% of AVF and 17.7% of CVC patients
were still treated with their initial vascular access type, where-
as 5.5% and 29.0% of AVF and CVC patients received a
Table 2 Likelihood of receiving
an AVF at start of hemodialysis
(unadjusted and adjusted odds
ratios and confidence intervals)
Variables OR unadjusted (95% CI) p value OR adjusted (95% CI) p value
Sex1
Female 0.69 (0.51–0.93) 0.02 0.67 (0.49–0.92) 0.01
Male (reference) 1.00 1.00
Age groups2
< 6 years 0.16 (0.08–0.23) < 0.001 0.16 (0.08–0.30) < 0.001
6 < 12 years 0.73 (0.48–1.13) 0.16 0.75 (0.49–1.16) 0.20
12–16 years 1.09 (0.75–1.57) 0.66 1.12 (0.77–1.63) 0.54
> 16 years (reference) 1.00 1.00
Primary renal disease3
Glomerulonephritis 0.53 (0.35–0.80) 0.003 0.51 (0.33–0.79) 0.002
CAKUT (reference) 1.00 1.00
Cystic kidney disease 0.81 (0.44–1.51) 0.51 0.81 (0.43–1.55) 0.53
Hereditary nephropathy 0.63 (0.36–1.12) 0.12 0.75 (0.40–1.39) 0.36
Ischemic renal failure 0.76 (0.18–3.16) 0.71 0.81 (0.18–3.57) 0.78
Hemolytic uremic syndrome 0.68 (0.30–1.54) 0.36 0.82 (0.35–1.95) 0.66
Metabolic disorders 0.33 (0.10–1.12) 0.08 0.43 (0.12–1.55) 0.20
Vasculitis 0.09 (0.02–0.39) 0.002 0.08 (0.02–0.38) 0.001
Missing/unknown diagnosis 0.42 (0.27–0.67) < 0.001 0.39 (0.24–0.64) < 0.001
1Adjusted for age at start of HD and PRD; 2Adjusted for sex; 3Adjusted for sex and age at start of HD
AVF arteriovenous fistula, CI confidence interval,OR odds ratio, CAKUT congenital anomalies of the kidney and
urinary tract, PRD primary renal disease
Fig. 2 Flow diagram of 713
incident hemodialysis (HD)
patients and their different
treatmentmodalities and switch to
another vascular access during
their follow-up time. Total follow-
up time was 1618 patient years
(AVF, 769 patient years; CVC,
849 patient years). During follow-
up, the overall crude rate of
switching was 113 per 1000
patient years at risk (AVF, 31.2
per 1000 patient years; CVC,
187.4 per 1000 patient years).
AVF arteriovenous fistula, CVC
central venous catheter, PD
peritoneal dialysis, TX (LD)
transplantation (living donor), TX
(DD) transplantation (deceased
donor)
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second vascular access, respectively (Fig. 3a). Similar results
were found after excluding patients under the age of 6 years.
Patients who started with an AVF were 91% less likely to
switch to a second vascular access as compared to those who
started with a CVC (adjusted hazard ratio (aHR), 0.09; 95%
CI, 0.05–0.16). Similar results were obtained when excluding
children younger than 6 years of age (aHR, 0.09; 95% CI,
0.05–0.15) and after excluding patients from France (aHR,
0.13; 95% CI, 0.07–0.26).
Patient survival
After a median follow-up of 0.78 (IQR, 0.25–1.33) years, 14
patients died (1 AVF; 13 CVC), resulting in a two-year patient
survival of 99.6% for AVF and 96.7% for CVC patients
(Fig. 3b). Cardiovascular disease was the cause of death in 4
patients (29%), infections in 2 (14%), the cause of death was
unknown for 2 (14%) patients, and 6 patients (43%) died from
other causes.
Access to renal transplantation
Overall transplantation rates (combining LD and DD) after
2 years were 67.4% for patients who started with an AVF
and 55.6% for those who started with a CVC. After adjust-
ment for age at start of RRT, sex, PRD, and country, the like-
lihood of receiving a renal transplant within 2 years was not
significantly different (Table 3). Similar results were obtained
after excluding patients younger than 6 years (aHR, 1.03; 95%
CI, 0.81–1.30), who received a renal transplant in the second
year after commencing HD (aHR, 0.92; 95% CI, 0.69–1.21),
and after excluding French patients (aHR, 1.06; 95% CI,
0.72–1.55).
However, transplantation rates in patients started on AVF
and CVC differed substantially with respect to donor type
(Table 3). Patients who started with an AVF were far more
likely to receive a kidney from a DD (62.1%), while CVC
patients more often received a kidney from a LD (Fig. 4a).
The timing of these transplantations was different. Most LD
transplantations occurred in the first 6 months after initiating
HD, while the proportion of DD transplantations was relative-
ly stable and persistently lower in CVC patients (Fig. 4b).
After excluding patients who were transplanted or died in
the first 6 months, the likelihood of DD transplantation was
still significantly higher in the AVF group compared with the
CVC group irrespective of country, age, sex, and PRD (aHR,
1.71; 95% CI, 1.26–2.31).
Discussion
This is the first study providing data on vascular access of
incident pediatric HD patients and their clinical course includ-
ing subsequent transplantation from several European coun-
tries. In European practice, more children started HD on a
CVC instead of an AVF. Current knowledge, such as barriers
for successful placement of an AVF in a child (patient being
too small, AVF not created in time, scheduled transplantation),
as well as a more stable clinical course with less switches of
vascular access with AFV were confirmed. For the first time,
data on HD vascular access were related to data on subsequent
transplantation: While overall transplantation rates were
equal, there were major differences in donor type and timing
of transplantation between children initiating HDwith AVF or
CVC. Central venous catheter patients more often received
LD transplants than AVF patients, mostly during the first
6 months after commencing HD. By contrast, CVC patients
were less likely than AVF patients to receive a transplant from
aDDwithin the first 2 years of dialysis, even when accounting
for differences in age, sex, PRD, and country of residence.
The observed high proportion of CVC as first vascular
access (56%) in European practice is in contrast to recommen-
dations in recent initiatives and guidelines, but in keeping with
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Fig. 3 Cumulative incidence curves for a switch of first access or change
to PD or b patient mortality stratified by first vascular access. HD
hemodialysis, AVF arteriovenous fistula, CVC central venous catheter,
PD peritoneal dialysis
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previous studies [10, 15, 16]. Some large US studies even
reported a CVC usage of 80–90% in incident HD children
[10, 17, 18]. In concordance with previous studies, we found
that patients who started HD on a CVC were significantly
younger than patients with an AVF, mainly because most
pre-school and pre-pubertal children started HD with a CVC
[15, 17, 19]. Interestingly, more than 10% of those who started
HD at an age under 6 years started with an AVF, demonstrat-
ing the option of creating anAVF in these young children [20].
As previously reported, also in our study, female patients were
at higher risk for receiving a CVC which underlines the need
for future studies of sex-specific factors in the decision-
making process in creation of vascular accesses [21–23].
Moreover, in keeping with data reported for the USA, patients
who started with a CVC were more often diagnosed with a
PRD associated with rapid renal function decline or with
delayed diagnosis, factors that might challenge pre-dialysis
care [24]. Pre-dialysis care represents another well-known de-
terminant for the choice of vascular access in HD patients, and
late referral has been associated with a lower use of AVF [25,
26]. Indeed, parameters for outcome of pre-dialysis care, such
as severity of anemia and stunted growth at onset of RRT,
were both associated with a reduced likelihood of receiving
an AVF [27–29]. Taken together, these data from the
ESPN/ERA-EDTARegistry successfully confirm previous re-
ports on barriers for AVF in the largest European population.
With regard to the clinical course on HD, CVC patients
were far more likely to switch to an AVF or to PD as compared
with AVF patients switching to CVC or PD. Data on infec-
tions or thromboembolic complications as potential cause for
failing of access are not provided to the Registry. As most of
these switches occurred within 3 months, however, we
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Fig. 4 a Cumulative incidence
for deceased donor (DD) or living
donor (LD) transplantation
stratified by first vascular access.
b Percentage of patients receiving
a kidney from a DD or LD
stratified by vascular access type
and time period since HD start.
HD hemodialysis, AVF
arteriovenous fistula, CVC central
venous catheter, LD living donor,
DD deceased donor
Table 3 Two-year access to
transplantation for patients with
different first vascular access
types (unadjusted and adjusted
hazard ratios [HR] for AVF vs.
CVC)
Unadjusted HR (95% CI) Adjusted HR (95% CI)
Overall 1.27 (1.03–1.57) 1.13 (0.90–1.41)
TX < 1 year since HD start 1.11 (0.85–1.44) 0.92 (0.69–1.21)
TX from living donor* 0.41 (0.23–0.74) 0.30 (0.16–0.54)
TX from deceased donor* 1.61 (1.27–2.04) 1.50 (1.17–1.93)
AVF arteriovenous fistula,CVC central venous catheter,HR hazard ratio,CI confidence interval, TX transplantation,
HD hemodialysis
*Source of TX (deceased donor or living donor) not provided in 2 patients
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speculate that the majority switches from CVC to AVF con-
stituted a delayed decision to create anAVF [26, 30, 31]. Thus,
CVC was likely provided in a relevant proportion of incident
HD patients as a “bridging therapy” until a permanent dialysis
access was created.
Use of the ESPN/ERA-EDTA Registry allows for the first
time to relate the choice of vascular HD access type to subse-
quent renal transplantation in a large European pediatric pop-
ulation. AVF patients and their parents typically have suffi-
cient time and information to consider all RRT options before
start of HD, including screening for potential LD for pre-
emptive transplantation [25, 26, 28, 32]. Thus, non-pre-
emptive LD was rare in the cohort of AVF patients. By con-
trast, CVC may be chosen as first treatment modality for elec-
tive as well as non-elective reasons [10, 15, 17–19, 33]. These
patients include the ones in whom LD was planned, but who
needed RRT before LD TX was completed, suggesting again
that CVC is offered as a “bridging therapy.” Indeed, in a US
study, CVC patients in whom transplantation was scheduled
had a shorter time to transplantation than AVF patients [17]. In
the Registry, the likelihood of receiving a LD transplant was
significantly higher for the CVC group, especially in the first
6 months after HD initiation.
Interestingly, CVC patients were less likely than AVF pa-
tients to receive a transplant from a DD within the first 2 years
of dialysis, even when accounting for differences in age, sex,
PRD, and country of residence. As the absolute proportion of
CVC patients receiving a LD is only 15.5%, anticipated LD
cannot be the only reason why the access to DD TX was
reduced in the CVC compared to the AVF group. Moreover,
after excluding patients who were transplanted or died within
the first 6 months, AVF patients still had a consistently higher
likelihood of DD transplantation than CVC patients. By this
time, expected LD transplants have already been performed,
and patients with poor initial clinical status should have stabi-
lized. We may speculate that other factors might contribute to
the lower likelihood of receiving DD transplantation in CVC
patients, such as severity and complexity of patients’ kidney
disease, extra-renal comorbidities, ethnic disparities, and local
center policies, but this requires further study.
The most important strength of our study is that we used
data from the ESPN/ERA-EDTA Registry, a meta-registry
that prospectively collects population-based data from
European national registries. While sensitivity analysis
suggests that our cohort is representative for the
European pediatric HD population, it should be noted that
vascular access type was only reported for 15% of all in-
cident HD patients included in the Registry. As a strength,
longitudinal data regarding changes in treatment, subse-
quent transplantation, and patient survival were available,
which enabled us to follow the course of HD treatment.
Further limitations of our work include the lack of data
on reasons to choose CVC or AVF, referral date, catheter
type, fistula creation date, infections and comorbidities,
and on local policies and center characteristics, which will
require further research in independent studies.
In conclusion, our study demonstrates that notwithstanding
the fistula-first initiative CVC still remains the major mode of
vascular access in European children despite a higher need for
switch to alternate access [9]. This practice is explained in part
by CVC being the only option in infants and its use as a
bridging therapy to living-related transplantation. Referral
timing, CKD progression rate, and the clinical condition at
start of dialysis might be additional determinants affecting
the choice of vascular access in children. While overall trans-
plantation rates were equal for both vascular access types
within the 2-years observation period, CVC patients and
AVF patients markedly differed in the likelihood to receive
their transplants from LD versus DD. This relationship be-
tween choice of hemodialysis vascular access type and donor
pattern of subsequent transplantation requires further study.
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